Author | Douglas K. Marks, MD | OncLive

Author | Douglas K. Marks, MD

Articles

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast Cancer

October 21, 2019

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Dr. Marks on PHENIX Trial Data in HER2+ Breast Cancer

September 10, 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

Dr. Marks on the Role of TKIs in HER2-Positive Breast Cancer

September 04, 2019

Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.

x